Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS Genet
Autores principales: Hamieh, Lana, Choueiri, Toni K., Ogórek, Barbara, Khabibullin, Damir, Rosebrock, Daniel, Livitz, Dimitri, Fay, Andre, Pignon, Jean-Christophe, McDermott, David F., Agarwal, Neeraj, Gao, Wenhua, Signoretti, Sabina, Kwiatkowski, David J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6181431/
https://ncbi.nlm.nih.gov/pubmed/30256787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pgen.1007679
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares